Clinicians Medication overview

The obesity medication landscape

Originally posted Apr 2026 · By Joe Zucchi, PA-C, MPAS

Download JPG ↓Original LinkedIn post ↗

1280 × 1280 px · PDF includes the original image and a link to this page.

Joe’s commentary

About this visual

A dated side-by-side overview of trial efficacy and approximate cash-pay pricing.

The obesity medication landscape continues to evolve quickly, so I updated this infographic for April 2026.

This chart is meant to provide a practical snapshot of the current FDA-approved obesity medication landscape, showing approximate average weight loss seen in major trials alongside estimated monthly cash pricing options.

New in this updated version:
• Wegovy HD (semaglutide 7.2 mg), added just below Zepbound, with about 20.7% average weight loss in STEP UP. Novo Nordisk also announced this week that Wegovy HD is now available nationwide.
• Foundayo (orforglipron), added as a new oral option, with about 12.4% average weight loss in ATTAIN-1. Lilly announced today that it is now available through LillyDirect and is shipping to retail pharmacies nationwide.

A few takeaways:
• The top end of obesity pharmacotherapy now extends beyond 20% average weight loss in trials
• Oral agents continue to become more competitive, which is a meaningful alternative for patients who prefer not to use injections
• Older medications still have a role, especially when cost, coverage, tolerability, or access are major limiting factors
• Obesity treatment is not one size fits all. The right choice depends on the patient, their medical history, insurance coverage, preferences, and long-term plan

One important caveat: this is not a head-to-head comparison.
These numbers come from different clinical trials with different patient populations, study designs, durations, and endpoints. Looking at them side by side can be helpful as a general overview, but it is not a statistically fair direct comparison between medications.

Pricing is also approximate and can change quickly depending on dose, eligibility, manufacturer programs, and insurance coverage.

Still, I hope this serves as a useful visual for clinicians, patients, and anyone trying to better understand where obesity medicine stands right now.

Sources & further reading

Original LinkedIn post and discussion ↗

Additional references appear in the infographic and the original LinkedIn discussion.

Related visuals

The obesity medication landscape

Pinch to zoom on touch devices. Open full image ↗